Arcus Biosciences Debt to Equity Ratio 2017-2022 | RCUS

Current and historical debt to equity ratio values for Arcus Biosciences (RCUS) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Arcus Biosciences debt/equity for the three months ending March 31, 2022 was 0.00.
Arcus Biosciences Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2022-03-31 $0.75B $0.80B 0.94
2021-12-31 $0.75B $0.84B 0.89
2021-09-30 $0.30B $0.54B 0.55
2021-06-30 $0.29B $0.61B 0.49
2021-03-31 $0.27B $0.67B 0.41
2020-12-31 $0.27B $0.50B 0.54
2020-09-30 $0.27B $0.54B 0.49
2020-06-30 $0.05B $0.43B 0.12
2020-03-31 $0.04B $0.14B 0.25
2019-12-31 $0.04B $0.16B 0.24
2019-09-30 $0.04B $0.18B 0.22
2019-06-30 $0.04B $0.20B 0.22
2019-03-31 $0.04B $0.22B 0.17
2018-12-31 $0.04B $0.24B 0.17
2018-09-30 $0.04B $0.25B 0.17
2018-06-30 $0.04B $0.26B 0.15
2018-03-31 $0.04B $0.27B 0.15
2017-12-31 $0.04B $0.15B 0.24
2017-09-30 $0.00B $0.00B 0.00
2017-06-30 $0.00B $0.00B 0.00
2017-03-31 $0.00B $0.00B 0.00
2016-12-31 $0.00B $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.901B $0.383B
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00